Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

Trump Linked to Mystery FDA Deal Granting Early Access to Powerful Weight-Loss Drug for Critical Patients

A 79-year-old patient received early access to Eli Lilly's experimental obesity drug retatrutide, sparking political and medical controversy amid speculation about the patient's identity.

International Business Times UK

White House denies Trump is the ‘well-connected’ man who gained compassionate access to obesity drug in April

A White House spokesman said theories that President Trump sought the drug were ‘baseless speculation’

The Independent UK

As Aussie waistlines expand, so do treatment costs

Most adult Australians are actually overweight or obese and that number is rising, research shows, with the problem taking a growing toll on health systems.

AAP

From analysis to the latest developments in health,
read the most diverse news in one place.

'It's not getting better': leading risk factor revealed for ill health and death

Almost 70 per cent of adults in Hunter New England are overweight or obese.

Newcastle Herald

ENDO 2026 Study Finds Most People Who Stop Ozempic or Tirzepatide for Type 2 Diabetes Eventually Restart Treatment

ENDO 2026 research published June 2026 via ScienceDaily found most GLP-1 users with type 2 diabetes who stop treatment eventually restart, driven by weight regain.

Medical Daily

Health company accused of using fake doctors for sales

Australians with diabetes, heart disease, obesity and menopause paid thousands and spoke with fake doctors who said their lives were at risk, a watchdog claims.

AAP

Ozempic Changed Obesity Treatment Forever — but Experts See a Bigger Medical Revolution Still Coming

A June 20, 2026 ScienceDaily report on a Gastroenterology commentary describes how GLP-1 drugs opened the door to a next era combining drugs, minimally invasive procedures, and precision medicine.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

Kids as young as six are being given weight-loss drugs as a way to curb obesity before it gets too late

About 21 percent of U.S. children between the ages of two and 19 have obesity, according to data from the Centers for Disease Control and Prevention

The Independent UK

Pfizer CFO Dave Denton to leave company in August

Pfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure raises investor concerns about Pfizer's 2026 forecast and succession plans. The company is preparing to enter the obesity drug market. Pfizer's shares were down in early trading. A search…

The Economic Times

Not all skinny: The French do get fat

With the French healthcare system now reimbursing the anti-obesity drugs Wegovy and Mounjaro, we explain what the strict conditions are to benefit from them. We discuss France's rates of obesity and the areas where they're highest. Finally, we discuss the common stereotype that French people don't get fat. While not…

France 24

GLP-1 Users Walk 560 Fewer Steps Per Day After Starting Ozempic or Wegovy, Fitbit Study Presented at ENDO 2026 Finds

ENDO 2026 study of 753 GLP-1 users found steps dropped 560/day and exercise fell 6 min/day after starting Ozempic or Wegovy. Muscle loss risk is the concern.

Medical Daily

India makes gains in child, maternal health but nutrition challenges persist: SBI report

India's latest health survey reveals significant improvements in maternal care and child vaccination rates. Stunting among children has seen a notable decline. However, modest gains in underweight and wasting indicate a need for comprehensive nutrition strategies. The survey also points to a rise in obesity among women. Fertility rates are…

The Economic Times

GLP-1 Drugs Like Ozempic Are Showing a 47 Percent Reduction in Breast Cancer Risk in a Major New Study — and Weight Loss May Not Explain It

A study presented at ASCO 2026 and published June 10, 2026 found that GLP-1 receptor agonists (semaglutide, tirzepatide) are associated with a 30–47% reduction in breast cancer risk among women with diabetes or obesity. The effect may operate through mechanisms beyond weight loss. Here is the full analysis.

Medical Daily

India risks becoming "unhealthier before it becomes richer," CEA V Anantha Nageswaran warns

India faces a health challenge before achieving wealth. Chief Economic Advisor V Anantha Nageswaran points to rising obesity and sedentary lifestyles. This impacts productivity and economic growth. He urges individuals to incorporate physical activity into daily routines. Improved health outcomes are seen as hidden growth potential for Viksit Bharat. This…

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Middle-aged adults taking GLP-1s for obesity can save $192K+ on lifetime medical costs, more if they don’t have college degrees, new study finds

The National Bureau of Economic Research paper's lead author hopes putting a dollar value on the benefits of GLP-1s will lead to better access

The Economic Times

India's weight-loss drug boom raises questions over healthcare priorities

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns about misuse for cosmetic reasons are growing. Regulators are intervening in advertising. The drugs also have side effects and can lead to weight regain. This boom is impacting pharmaceutical research priorities.

The Economic Times

UK approves Novo weight-loss pill to edge open European market

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatment. Over 10 million people with obesity in the UK now have an alternative to injections. Drugmakers are racing to expand use of these transformative medicines. The market is expected…

The Guardian - UK

Wegovy weight-loss pills to be available for patients in UK to buy

Regulator approval means patients who meet criteria will be able to purchase tablets with private prescription

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Scientists Unveil a Diabetes and Obesity Pill That Burns Fat Through Muscle — Without Killing Your Appetite or Causing Muscle Loss

Karolinska/Stockholm University published a new obesity-diabetes pill in Cell (June 2026) that activates muscle metabolism to burn fat and lower blood sugar without appetite suppression or muscle loss. Safe in early human trial.

The Independent UK

First ever guidelines released to screen for condition that impacts 9 in 10 Americans

Doctors say earlier screening could help save lives

Medical Daily

Medicare Is About to Cover Weight-Loss Drugs for the First Time — Here's What the GLP-1 Bridge Program Means for Millions of Americans with Obesity

Medicare's GLP-1 Bridge launches July 1, 2026, offering eligible Part D enrollees Wegovy and Zepbound for $50/month — the first-ever Medicare coverage for obesity-specific GLP-1 drugs.

The Independent UK

New daily weight loss pill helps people shed 10 per cent of body weight

The pill doesn’t have the fasting requirements of many other weight loss drugs

MarketBeat

Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near

Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Yuval Cohen outlined the company’s near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies fireside chat hosted by biotech analyst Amin Makarem. Cohen said the Norwood, Massachusetts-based dru

The Independent UK

Why a dad bod isn’t as harmless as it seems

Approximately 100 million Americans live with obesity — a number that could more than double by 2050

The Conversation

No, regaining weight after losing it won’t permanently damage your metabolism – new research

When it comes to losing weight, the fear of “ruining your metabolism” is widespread. Indeed, many people who have lost weight and then put it back on feel that every failed attempt leaves them worse off than before, with more fat, less muscle, greater hunger, lower energy, and an ever-diminishing…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.